ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Wacker Chemie and CordenPharma are part of a $3.1 billion program to secure messenger RNA (mRNA) vaccine production for Germany. The chemical firms are preparing to produce 80 million doses per year if the COVID-19 pandemic persists or the need arises for vaccines to address a new pandemic. Wacker would manufacture mRNA and the plasmid DNA starting material. CordenPharma would produce lipids and Wacker would turn them into lipid nanoparticles. CordenPharma would develop vaccine formulations and perform sterile filling and packaging of vaccines. Vaccine makers BioNTech, Celonic, and IDT Biologika are also in the German program, as is a partnership between CureVac and GlaxoSmithKline.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X